Sample Analyses Sample Clauses

Sample Analyses. Syndax shall provide to Genentech the Samples necessary for Genentech to perform the Sample Analyses for which Genentech is responsible under the Sample Analysis Plan. Each Party *** shall perform (directly or through a Third Party on its behalf) the Sample Analyses for which it is responsible in the Sample Analysis Plan (to the extent Samples are available, in accordance with the priorities in the Sample Analysis Plan). Each Party shall provide to the other Party the Sample Data for the Sample Analyses such Party performed (regardless of which Party owns such Sample Data), via electronic data transfer, in the format and using the media agreed to by the Parties, on the timelines in the Sample Analysis Plan. Neither Party shall use the Samples for any purpose other than performing the Sample Analyses for which it is responsible, without the prior written consent of the other Party.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Sample Analyses. Analyses are required for only those analytes that are a component of the participant’s routine analytical workload or compliance requirements (i.e., a complete analysis of the sample may not be required). Laboratories must report results for a targeted analyte if the determination is typically given by the analytical methodology utilized. For example, if Pu-238 and Pu-239 are targeted analytes, and results for Pu-239 are reported utilizing alpha spectrometry, the results for Pu-238 must also be reported. The same analytical procedures employed for routine analyses should also be utilized for MAPEP standards. MAPEP, however, may also be used to develop new analytical methods or demonstrate proof of process. Participants are typically allowed 60 calendar days to complete those analyses not controlled by regulatory holding times. The deadline for reporting results is specified for each sample distribution. Although analytical methods are not prescribed by MAPEP, standard analytical procedures will be utilized to independently characterize and verify the MAPEP standards. These analytical techniques include alpha spectrometry, beta counting, gamma spectrometry, inductively coupled plasma (ICP) atomic emission spectroscopy, ICP mass spectrometry, gas chromatography, gas chromatography/mass spectrometry, and other common analytical methods. Activities for radiological analytes are typically sufficient to provide a 5-10% counting uncertainty with a reasonable sample size and count time. Similar uncertainties should be achievable for most stable inorganic/organic analytes. The amount of sample is, however, limited. Therefore, the activity and concentration ranges indicated in the sample description must be used to select the optimum quantity of sample for each analysis.
Sample 1
Sample Analyses. (Sample digestion fee is not included in unit rate for individual metals by ICP & ICP/MS) Chromium VI (24 hour Hold Time for waters) EPA 218.6 80 Chromium VI (24 hour Hold Time for waters) EPA 7196A 50 Chromium VI (soil/solid matrix) EPA 7196A/3060A 55 Chromium VI (24 hour Hold Time for waters) EPA 7199 75 Chromium VI (soil/solid matrix) EPA 7199/3060A 80 Individual Metals by ICP EPA 6010B or 200.7 8 Individual Metals by ICP/MS EPA 6020 or 200.8 15 Mercury by Cold Vapor AA (includes digestion) EPA 7470A/7471A or 245.1 25 Mercury – Low Level (water) EPA 1631E 85 CA Title 22 – CAM 17 Metals: Sb, As, Ba, Be, Cd, Cr(t), Co, Cu, EPA 6010B & 7470A or 0000X 00 Xx, Xx, Xx, Xx, Xx, Xx, Xx, X, Xx CA Title 22 – CAM 17 Metals: Sb, As, Ba, Be, Cd, Cr(t), Co, Cu, EPA 6020 & 7470A or 0000X 000 Xx, Xx, Xx, Xx, Xx, Xx, Xx, X, Xx Priority Pollutant Metals: Sb, As, Be, Cd, Cr(t), Cu, Pb, Hg, Ni, EPA 200.7 & 245.1 or 00 Xx, Xx, Xx, Xx EPA 6010B & 7470A or 7471A Priority Pollutant Metals: Sb, As, Be, Cd, Cr(t), Cu, Xx, Xx, Xx, Xx, Xx, Xx, Xx EPA 200.8 & 245.1 or EPA 6020 & 7470A or 7471A 100 TCLP (RCRA) Metals: As, Xx, Xx, Xx(x), Xx, Xx, Xx, Xx XXX 0000X & 7470A or 7471A 75 ICP Metals Scan: Al, Xx, Xx, Xx, Xx, X, Xx, Xx, Cr(t), Co, Cu, Fe, EPA 6010B or 200.7 00 Xx, Xx, Xx, Xx, Ni, P, K, Se, Si, Sr, Ag, Na, Sn, Ti, Tl, V, Zn ICP/MS Metals Scan: Al, Xx, Xx, Xx, Xx, X, Xx, Xx, Cr(t), Co, Cu, EPA 6020 or 200.8 000 Xx, Xx, Xx, Xx, Xx, Ni, K, Se, Sr, Ag, Na, Sn, Ti, Tl, V, Zn Appendix I List: Sb, As, Ba, Be, Cd, Cr(t), Co, Cu, Xx, Xx, Xx, Xx, XXX 0000X & 7470A or 7471A 80 Tl, V, Zn, Hg Appendix I List: Xx, Xx, Xx, Xx, Xx, Xx(x), Xx, Cu, Xx, Xx, Xx, Xx, XXX 0000 & 7470A or 7471A 100 Tl, V, Zn, Hg Appendix II/IX List: Sb, As, Ba, Be, Cd, Cr(t), Co, Cu, Pb, Ni, Se, EPA 6010B & 7470A or 0000X 00 Xx, Xx, Xx, X, Xx, Xx Appendix II/IX List: Sb, As, Ba, Be, Cd, Cr(t), Co, Cu, Pb, Ni, Se, EPA 6020 & 7470A or 0000X 000 Xx, Xx, Xx, X, Xx, Xx ICP/MS Metals Scan with Reductive Precipitation Preparation: SOP M225/EPA 6020/6020A or 200.8 275 As, Be, Cd, Cr, Co, Cu, Xx, Xx, Xx, Xx, Xx, Xx Sea Water Metals: Al, Sb, As, Ba, Cd, Cr, Co, Cu, Fe, Pb, Mn, Mo, EPA 1640 (Water) 275 Se, Ag, Tl, V, Zn Parameters shown in Bold have short Hold Times WET CHEMISTRY ANALYSIS METHOD PRICE $ Acidity SM 2310 B (EPA 305.1) 30 Ash Free Dry Mass SM 10300 C 20 Anions by XX (X, Xx, Xx, XX0, XX0, XX0, o-PO4) (48 hour Hold Time) EPA 300.0/9056 50 Any single anion EPA 300.0/9056 20 Any two anions EPA 300.0/9056 30 Any three...
Sample 1
Sample Analyses. Sponsor shall provide to Non-Sponsor the Samples necessary for Non-Sponsor to perform the Sample Analyses for which Non-Sponsor is responsible under the Sample Analyses Plan. Each Party, at its own expense, shall perform the Sample Analyses for which it is responsible in the Sample Analyses Plan (to the extent Samples are available, in accordance with the priorities in the Sample Analyses Plan). Each Party shall provide to the other Party the Sample Data for the Sample Analyses such Party performed (regardless of which Party owns such Sample Data), via electronic data transfer, in the format and using the media agreed to by the Parties in accordance with the timelines in the Sample Analyses Plan. Neither Party shall use the Samples for any purpose other than performing the Sample Analyses for which it is responsible, without the prior written consent of the other Party. Unless otherwise agreed by the Parties, all Samples supplied under this Agreement shall be provided [*]
Sample 1

Related to Sample Analyses

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Risk Analysis The Custodian will provide the Fund with a Risk Analysis with respect to Securities Depositories operating in the countries listed in Appendix B. If the Custodian is unable to provide a Risk Analysis with respect to a particular Securities Depository, it will notify the Fund. If a new Securities Depository commences operation in one of the Appendix B countries, the Custodian will provide the Fund with a Risk Analysis in a reasonably practicable time after such Securities Depository becomes operational. If a new country is added to Appendix B, the Custodian will provide the Fund with a Risk Analysis with respect to each Securities Depository in that country within a reasonably practicable time after the addition of the country to Appendix B.

  • Special Analyses It is hereby certified that these regulations will not have a significant economic impact on a substantial number of small entities. This certification is based on the fact that it is unlikely that a substantial number of small entities will hold REMIC residual interests. Therefore, a Regulatory Flexibility Analysis under the Regulatory Flexibility Act (5 U.S.C. chapter 6) is not required. It has been determined that this Treasury decision is not a significant regulatory action as defined in Executive Order 12866. Therefore, a regulatory assessment is not required. It also has been determined that sections 553(b) and 553(d) of the Administrative Procedure Act (5 U.S.C. chapter 5) do not apply to these regulations. Drafting Information The principal author of these regulations is Xxxxxxxx Xxxxxxxxxx. However, other personnel from the IRS and Treasury Department participated in their development. List of Subjects 26 CFR Part 1 Income taxes, Reporting and record keeping requirements.

  • Sampling and Analysis The sampling and analysis of the coal delivered hereunder shall be performed by Buyer upon delivery of the coal to Buyer’s facility, and the results thereof shall be accepted and used as defining the quality and characteristics of the coal delivered under this Agreement and as the Payment Analysis. All analyses shall be made in Buyer’s laboratory at Buyer’s expense in accordance with ASTM standards where applicable, or industry-accepted standards in other cases. Samples for analyses shall be taken in accordance with ASTM standards or other methods mutually acceptable to both parties. Seller shall transmit its “as loaded” quality analysis to Buyer as soon as possible. Seller’s “as-loaded” quality shall be the Payment Analysis only when Buyer’s sampler and/or scales are inoperable, or if Buyer fails to obtain a sample upon unloading. Seller represents that it is familiar with Buyer’s sampling and analysis practices, and that it finds them to be acceptable. Buyer shall notify Seller in writing of any significant changes in Buyer’s sampling and analysis practices. Any such changes in Buyer’s sampling and analysis practices shall, except for ASTM or industry-accepted changes in practices, provide for no less accuracy than the sampling and analysis practices existing at the time of the execution of this Agreement, unless the Parties otherwise mutually agree. Each sample taken by Buyer shall be divided into four (4) parts and put into airtight containers, properly labeled and sealed. One (1) part shall be used for analysis by Buyer. One (1) part shall be used by Buyer as a check sample, if Buyer in its sole judgment determines it is XXXXXXXXX COAL COMPANY, INC. LG&E/KU Xxxxxxxx Xx. X00000 necessary. One (1) part shall be retained by Buyer until thirty (30) days after the sample is taken (“Disposal Date”), and shall be delivered to Seller for analysis if Seller so requests before the Disposal Date. One (1) part (the “Referee Sample”) shall be retained by Buyer until the Disposal Date. Seller shall be given copies of all analyses made by Buyer by the fifth (5th) business day of the month following the month of unloading. In addition, Buyer shall send Seller weekly analyses of coal unloaded at Buyer’s facilities. Seller, on reasonable notice to Buyer, shall have the right to have a representative present to observe the sampling and analyses performed by Buyer, Unless Seller requests an analysis of the Referee Sample before the Disposal Date, Buyer’s analysis shall be used to determine the quality of the coal delivered hereunder and shall be the Payment Analysis. The Monthly Weighted Averages of specifications referenced in §6.1 shall be based on the individual Shipment analyses. If any dispute arises with regard to the analysis of any sample before the Disposal Date for such sample, the Referee Sample retained by Buyer shall be submitted for analysis to an independent commercial testing laboratory (“Independent Lab”) mutually chosen by Buyer and Seller. For each coal quality specification in question, if the analysis of the Independent Lab differs by more than the applicable ASTM reproducibility standards, the Independent Lab results will govern, and the prior analysis shall be disregarded. All testing of the Referee Sample by the Independent Lab shall be at requestor’s expense unless the Independent Lab results differ from the original Payment Analysis for any specification by more than the applicable ASTM reproducibility standards as to that specification. In such case, the cost of the analysis made by the Independent Lab shall be borne by the party who provided the original Payment Analysis. XXXXXXXXX COAL COMPANY, INC. LG&E/KU Contract No. J14004

  • Investment Analysis and Implementation In carrying out its obligations under Section 1 hereof, the Advisor shall:

  • Investment Analysis and Commentary The Subadviser will provide quarterly performance analysis and market commentary (the “Investment Report”) during the term of this Agreement. The Investment Reports are due within 10 days after the end of each quarter. In addition, interim Investment Reports shall be issued at such times as may be mutually agreed upon by the Adviser and Subadviser; provided however, that any such interim Investment Report will be due within 10 days of the end of the month in which such agreement is reached between the Adviser and Subadviser. The subject of each Investment Report shall be mutually agreed upon. The Adviser is freely able to publicly distribute the Investment Report.

  • Escrow Analysis If applicable, with respect to each Mortgage Loan, the Seller has within the last twelve months (unless such Mortgage was originated within such twelve month period) analyzed the required Escrow Payments for each Mortgage and adjusted the amount of such payments so that, assuming all required payments are timely made, any deficiency will be eliminated on or before the first anniversary of such analysis, or any overage will be refunded to the Mortgagor, in accordance with RESPA and any other applicable law;

  • Samples Physical examples of materials, equipment, or workmanship that are representative of some portion of the Work and that establish the standards by which such portion of the Work will be judged. The Contractor shall furnish for approval all samples required by the Contract Documents. The Work shall be in accordance with approved samples.

  • Protocols Each party hereby agrees that the inclusion of additional protocols may be required to make this Agreement specific. All such protocols shall be negotiated, determined and agreed upon by both parties hereto.

  • Independent Analysis Each Party hereby confirms that its decision to execute this Agreement has been based upon its independent assessment of documents and information available to it, as it has deemed appropriate.

Time is Money Join Law Insider Premium to draft better contracts faster.